UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
On September 30, 2026, Sarepta reported a 3.32-point two-year NSAA advantage for 25 older ambulatory ELEVIDYS patients over 99 external controls. The FDA’s February 28, 2027 target date for AMONDYS 45 and VYONDYS 53, repeat-dose siRNA data guided for the second half of 2026 and ENDEAVOR cohort 8 data guided for Q1 2027 frame the next phase, alongside the boxed liver warning and about $1.05 billion of convertible-note principal.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
The FDA accepted the supplemental applications that seek conversion of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) from accelerated to traditional approval, and set a target action date of February 28, 2027. The applications rest on ESSENCE, which missed its primary endpoint, together with additional analyses and real-world evidence. A target date is when the agency aims to act, not a commitment to approve. Before it, repeat-dose data for SRP-1001 and SRP-1003 are guided for the second half of 2026 without an exact date. Source
At June 30, 2026, Sarepta owed $158.6 million of 1.25% notes due September 15, 2027 and $893.4 million of 4.875% notes due September 1, 2030. In the second quarter the earnings-per-share note excluded 16.0 million shares issuable under the convertible debt and 11.8 million under equity plans as anti-dilutive. On September 30, 2026 the company granted a further 211,070 restricted stock units to new hires. ELEVIDYS carries a boxed warning for acute liver injury and acute liver failure. Every number here comes from the Q2 2026 Form 10-Q and company releases, not from market data. Source
The constructive case is that investors can eventually value Sarepta as a commercial rare-disease business with a second technology platform, rather than pricing every program through the difficulties of ELEVIDYS. The existing PMO franchise provides operating revenue while SRP-1001 and SRP-1003 test whether effective muscle delivery can produce a clinically useful response. Favorable repeat-dose results would matter more than another encouraging laboratory result: they could support a development plan with credible dosing, measurable patient benefit and a clearer route toward larger studies.
The February FDA decision offers a different route to reduced uncertainty. Traditional approval for AMONDYS 45 and VYONDYS 53 would address an important overhang on marketed products. An acceptable ENDEAVOR cohort 8 safety profile could then support further regulatory discussions in non-ambulatory Duchenne. This sequence gives the stock several opportunities for the evidence to improve. With roughly a quarter of estimated float sold short, an unexpected improvement could be amplified by position unwinds. None of those outcomes requires assuming that a squeeze is inevitable, or that a successful early trial already establishes commercial value.
Sources: FDA accepts AMONDYS 45 and VYONDYS 53 sNDAs, June 30, 2026 · Q2 2026 results and outlook, August 5, 2026 · Nasdaq short interest, September 15, 2026 settlement.
The skeptical case is equally concrete. The market is evaluating products with existing safety and confirmatory-evidence problems, not an untouched pipeline. ESSENCE failed its prespecified primary endpoint, and ELEVIDYS has a boxed liver warning and a narrower U.S. indication. A regulator can accept an application and still require more evidence. Revenue also has to fund debt, operating needs, manufacturing commitments and licensed-program costs; a large gross cash balance is not the same thing as excess cash belonging to shareholders.
The siRNA programs are still early. Drug delivery, target suppression and improved muscle function are different steps, and a small cohort may not show all three. A disappointing clinical signal could leave shareholders relying more heavily on the very commercial franchise under regulatory review. High short interest may amplify a positive surprise, but it can also reflect well-founded concerns or hedged positions. The damaging outcome is a combination of weaker product economics, delayed development and more expensive financing; that combination can destroy equity value even if the company continues operating.
Sources: ESSENCE regulatory update, March 19, 2026 · FDA ELEVIDYS label and boxed warning, November 14, 2025 · June 30, 2026 Form 10-Q, SEC.
October 2, 2026. The newest clinical disclosure is the September 30 World Muscle Society presentation: in 25 boys dosed with ELEVIDYS at ages 8–12, the two-year NSAA change exceeded that of 99 matched external controls by 3.32 points (95% CI 1.24–5.41; nominal p=0.0022), and two timed-function tests moved in the same direction. The comparison is externally controlled, not randomized, and it does not change the U.S. label, which since November 2025 covers only ambulatory patients aged four and older under a boxed liver warning.
The financial baseline is still the second quarter: $328.7 million of net product revenue, $945.0 million of cash, investments and restricted cash at June 30, 2026, full-year net product revenue guidance narrowed to $1.2–1.3 billion, and about $1.052 billion of convertible-note principal. The $39.0 million AAV patent settlement signed on September 23 was accrued in Q2 and is payable within ten days of signing. The next dated regulatory event is the FDA’s February 28, 2027 target action date for AMONDYS 45 and VYONDYS 53.
Update through October 14, 2026. After the September 30 WMS data, Sarepta announced a routine inducement grant to new employees and, on October 14, presented preclinical SRP-1003 data in DM1 at the Oligonucleotide Therapeutics Society meeting (release); EDGAR shows no Form 8-K after the September 23 settlement filing. September 30, 2026 inducement-grant release
Sarepta combines an established commercial business with early siRNA programs and substantial regulatory risk. Three event blocks through March 2027 can change the debate: repeat-dose FSHD/DM1 data, the February 28 PMO approval-conversion decision, and ENDEAVOR cohort 8 safety data. The short interest is high; the clinical and balance-sheet reasons for skepticism are real.
At the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (poster P-066), Sarepta presented preclinical data for SRP-1003, its siRNA candidate for myotonic dystrophy type 1 (DM1). In DM1 patient-derived muscle cells, SRP-1003 reduced DMPK mRNA in a dose-dependent manner in both the nucleus and the cytoplasm, by up to approximately 80% in each, confirmed with three methods (RNA FISH, compartment-fractionated ddPCR and RNAscope); a scrambled control siRNA showed no knockdown. In the DMSXL mouse model it reduced nuclear RNA foci in skeletal muscle, diaphragm and myocardium, and in a second DM1 mouse model a surrogate siRNA produced dose-dependent correction of MBNL-dependent mis-splicing. SRP-1003 showed sustained exposure in muscle for up to 16 weeks after a single intravenous dose. These are laboratory and animal results, not clinical evidence in patients; Sarepta said it plans to share results from the ongoing Phase 1/2 study SRP-1003-101 later this year.
RBC Capital Markets kept a Sector Perform rating on Sarepta and lowered its price target to $17 from $19, as reported on October 8 by Dow Jones Newswires. A third-party opinion, not a Merlintrader view and not a recommendation.
H.C. Wainwright maintained its $5 price target on Sarepta on October 5, 2026, according to Dow Jones Newswires. A single broker’s reiteration, not a consensus view. A third-party opinion, not a Merlintrader view and not a recommendation.
Sarepta presented two-year outcomes for 25 ambulatory patients dosed at ages 8–12, compared with 99 external controls. A separate analysis in children aged 2 to under 3 reports biological expression at Week 12. These analyses do not show a new randomized result or remove known safety risks.
ENDURE and U.S. postmarketing posters provide observational safety data. The small sirolimus subgroup does not show protection against liver injury or change the ELEVIDYS label.
Sarepta granted 211,070 restricted stock units in aggregate to 37 people hired in the third quarter, under its 2024 Employment Commencement Incentive Plan. No options were granted; the units vest in four equal annual instalments. The grant adds modestly to future share supply.
A settlement with REGENXBIO, UPenn and Catalent resolves specified patent disputes. The amount was already accrued in Q2, but the settlement creates a near-term cash payment.
Novartis disclosed that del-desiran missed HARBOR’s primary video hand-opening endpoint. This is a sector read-through, not a Sarepta trial result.
The full deep dive has the answer’s building blocks: cash, dilution, catalysts and risks, every figure sourced.
Free. No signup. You decide, we don’t recommend.
| Scenario | Evidence needed | How equity value could respond |
|---|---|---|
| Constructive | Coherent repeat-dose RNA results; favorable PMO regulatory resolution; stable commercial demand and manageable cash use | Greater confidence in franchise durability plus a higher value assigned to the pipeline could support a rerating. |
| Mixed | Biomarker progress with inconclusive functional evidence; more regulatory work; commercial stabilization without clear growth | More development time and spending may offset better biology; volatility can persist without a durable rerating. |
| Adverse | New material safety issue, weak repeat-dose results, adverse PMO action or deterioration in product economics | Lower cash-flow value and greater financing needs can reinforce each other, increasing downside and dilution risk. |
These are conditional analytical scenarios, not forecasts or assigned probabilities. The dated observations that would contradict the constructive reading are listed in the next section.
The reading presented here is that Sarepta can hold its commercial base while three dated tests, the FDA decision on two PMO drugs, ENDEAVOR cohort 8 and the repeat-dose siRNA data, decide whether a second chapter exists. Each observation below would contradict it and would appear in a company release, an SEC filing or an FDA document.
These are tests of the reading, not predictions. None of them had occurred as of October 2, 2026.
Sarepta is a high-risk commercial biotech whose next chapter depends on protecting an existing business while establishing a new one. That distinction matters. The PMO drugs and ELEVIDYS already generate revenue, but their economics and regulatory status are central uncertainties. The siRNA assets offer diversification, yet their investment relevance depends on the quality of new clinical evidence rather than the size of a theoretical market.
The most useful way to read the next six months is as three separate tests. The first is whether repeated dosing in FSHD and DM1 produces a coherent biological and clinical response. The second is whether the FDA accepts the totality of the PMO evidence for traditional approval. The third is whether enhanced immunosuppression produces a sufficiently reassuring ELEVIDYS safety dataset to support a regulatory path in a population no longer included in the U.S. label. Success in one test does not automatically answer the others.
Merlintrader treats the company as an event-driven research watchlist candidate. It does not assign an investment rating, price target or probability of approval. The most defensible positive argument is a sequence of observable improvements; the central negative argument is that the existing franchise could deteriorate before the next platform becomes valuable.
Sarepta was incorporated in Oregon in 1980 and later reincorporated in Delaware. Its headquarters are in Cambridge, Massachusetts. As of October 2026 it markets three exon-skipping medicines and one gene therapy in the United States. The Arrowhead agreement expanded its scope beyond Duchenne into muscle, pulmonary and central nervous system diseases. This is a substantial strategic change: Sarepta is attempting to connect a commercial rare-disease infrastructure with a broader RNA-development portfolio.
Sources: 2025 Form 10-K, filed March 2, 2026 · Sarepta pipeline, April 2026 program inventory.
The June 2026 filing reports that the July 2025 restructuring reduced the workforce by approximately 36%. Sarepta Q2 2026 Form 10-Q.
Michael Severino, M.D., became CEO and a director on July 28, 2026. He previously led Tessera and held senior positions at AbbVie, Amgen and Merck. Doug Ingram left the CEO and board roles and remains a consultant through December 2026. M. Kathleen Behrens is board chair. The relevant question is therefore Severino’s execution; the former CEO no longer runs the company.
Sources: CEO appointment, July 27, 2026 · Michael Severino biography.
The July employment filing describes an approximately $35 million grant-date equity package, including annual, new-hire and make-whole components. It comprises restricted stock units and premium-priced options with vesting conditions. This is compensation, not an open-market purchase by the new CEO. The distinction is essential when discussing “insider conviction.” The proxy describes separate CEO and non-executive chair roles, independent committee oversight and an insider hedging prohibition. Those mechanisms establish a governance framework; the test is how they work when safety, spending and shareholder interests collide.
Sources: CEO employment and equity arrangements, July 27, 2026 · 2026 proxy statement.
| Product | Approach / population | What investors must distinguish |
|---|---|---|
| EXONDYS 51 — eteplirsen | Exon 51 skipping in mutation-amenable Duchenne | Marketed under accelerated approval; not one of the two products in the February 2027 conversion event. |
| AMONDYS 45 — casimersen | Exon 45 skipping | Conversion application under review; ESSENCE and real-world evidence are relevant. |
| VYONDYS 53 — golodirsen | Exon 53 skipping | Shares the ESSENCE evidence base and FDA target date with AMONDYS 45. |
| ELEVIDYS — delandistrogene moxeparvovec-rokl | AAVrh74 micro-dystrophin gene transfer | U.S. indication restricted to ambulatory patients aged 4+; boxed liver warning. |
Sources: FDA accepts AMONDYS 45 and VYONDYS 53 sNDAs, June 30, 2026 · FDA ELEVIDYS label and boxed warning, November 14, 2025.
The PMO products are mutation-specific medicines; their eligible populations cannot simply be added to a gene-therapy market model without considering overlap. They also use a different technology from ELEVIDYS. A gene-therapy safety event is not evidence that every RNA drug has the same mechanism of harm. Equally, a favorable PMO regulatory decision would not resolve the gene-therapy safety question. Keeping these distinctions intact prevents a portfolio-level story from becoming scientifically misleading.
SRP-1001 and SRP-1003 use small interfering RNA coupled to a ligand that targets the αvβ6 integrin pathway. SRP-1001 is intended to reduce DUX4-related disease biology in FSHD1; SRP-1003 targets DMPK messenger RNA in DM1. The initial Phase 1/2 programs use ascending-dose, placebo-controlled designs, with both single-dose and multiple-dose components.
Sources: First siRNA clinical results, March 25, 2026.
For an investor, the causal chain is straightforward but demanding: enough drug must reach the relevant cells; the intended RNA target must change; downstream disease biology must respond; and the patient must experience a benefit that is meaningful and sustainable. Measuring the first link does not prove the last. Exposure can support dose selection, and target suppression can support biological plausibility, yet neither automatically establishes a registration-quality clinical result.
The NMSG poster describes a Phase 1/2 study in genetically confirmed FSHD1, with safety and tolerability primary and muscle delivery, DUX4-related measures, creatine kinase and functional assessments among the additional endpoints. Its early single-dose findings included muscle exposure and suppression of DUX4-regulated gene composites. These were small, exploratory analyses; they are not proof of long-term functional recovery.
The poster reported no dose-limiting safety signal and an unrelated serious event of chest discomfort. It also included participants assigned to multiple-dose cohorts, but the presented exposure analysis included first-dose measurements. The September poster is not the complete forthcoming longitudinal MAD result. The next readout needs to explain outcomes across repeated administrations and the evaluable sample for each endpoint.
Sources: NMSG 2026 SRP-1001 poster.
The strongest update would align several observations: consistent target-related changes, a plausible dose response, durability over the dosing interval, an interpretable functional direction and no offsetting safety problem. A mixed dataset could still justify further development while disappointing the stock. If the biomarker result improves but the functional assessments remain noisy, the right conclusion may be that more evidence is needed, rather than that the program has succeeded or failed commercially. FSHD heterogeneity makes transparent denominators and missing-data handling particularly important.
SRP-1003’s Phase 1/2 trial evaluates safety and pharmacokinetics, with muscle exposure, DMPK knockdown, splicing indices and functional measures in the endpoint framework. The September NMSG poster’s dataset included 36 participants; most reported treatment-emergent adverse events were mild or moderate. Two participants experienced three serious events, including a fatal arrhythmia, which investigators considered unrelated to study drug. That attribution is part of the finding.
The poster presented early delivery and exposure information rather than a definitive controlled functional outcome from the full repeat-dose program. Future data should identify dose, duration, analysis population and the relationship between molecular changes and clinical measurements. Because DM1 is multisystem disease, benefit in one muscle assessment also should not be generalized to every manifestation.
Sources: NMSG 2026 SRP-1003 poster.
September’s HARBOR result makes that standard especially relevant. Novartis reported that del-desiran did not achieve statistical significance on its primary video hand-opening endpoint, despite signs of activity in other analyses. This does not show that SRP-1003 will fail: the molecules, delivery approaches and studies differ. It does show why promising early biomarkers and a later successful pivotal endpoint are not interchangeable. Investors should examine endpoint reliability and placebo behavior alongside the drug’s biology.
Sources: Novartis HARBOR Phase III results, September 8, 2026.
The March 19 company update describes a sensitivity analysis excluding 23 participants whose baseline stair-climb assessment fell in the COVID-19 impact period. It reported a 0.12 steps-per-second difference at week 96 with P=0.050, compared with the original primary-endpoint result of 0.06 and P=0.309. This modified analysis provides context for the regulatory discussion; it does not change the failure of the prespecified primary analysis to reach statistical significance. Sarepta regulatory update on AMONDYS 45 and VYONDYS 53.
ESSENCE was a randomized, blinded, placebo-controlled confirmatory study of casimersen and golodirsen in Duchenne. It failed its prespecified primary endpoint: change in four-step ascend velocity at week 96. The March 2026 presentation reported a least-squares difference of 0.06 steps per second and P=0.309. The earlier November release reported a difference of 0.05 steps per second; both disclosures agree that the primary analysis was not statistically significant.
Sources: ESSENCE regulatory update, March 19, 2026 · ESSENCE initial topline disclosure, November 3, 2025.
The applications seek conversion from accelerated to traditional approval, with a February 28, 2027 FDA target action date. The company supports them with ESSENCE, additional analyses and published real-world experience. There is a legitimate distinction between saying those sources may inform a totality-of-evidence review and saying they erase the failed primary endpoint. The latter would overstate the evidence.
Sources: FDA accepts AMONDYS 45 and VYONDYS 53 sNDAs, June 30, 2026.
The equity issue is protection of an existing revenue stream and removal of uncertainty, not the launch of two entirely new drugs. Because both applications share a study and a date, Merlintrader counts them as one regulatory event block. A favorable outcome could improve the durability investors assign to the franchise. A request for additional work, adverse label action or rejection of conversion could preserve or intensify uncertainty. The eventual FDA documents, conditions and wording will matter more than a simplistic “accepted versus rejected” headline.
WMS: two-year ELEVIDYS outcomes and early data in younger children — September 30, 2026. Patients dosed at ages 8–12 from EMBARK and ENDEAVOR (n=25) were compared with an external-control group (n=99). The company reports a two-year least-squares mean difference of 3.32 NSAA points (95% CI 1.24–5.41; nominal p=0.0022). Rise-from-floor velocity improved by 0.041 rises per second (95% CI 0.016–0.066; nominal p=0.0019) and 10-meter walk/run velocity by 0.195 meters per second (95% CI 0.046–0.345; nominal p=0.0114) against the same controls. The prospective matching strategy helps comparability but cannot eliminate confounding inherent to a nonrandomized external control.
The younger-patient analysis includes ENDEAVOR cohort 6 (n=6) and ENVOL cohort B (n=3), ages at least 2 and under 3, with micro-dystrophin expression and localization assessed at Week 12. Mean expression by western blot was 93.9% of control in the ENDEAVOR cohort and 72.8% in the ENVOL cohort, with 79.9% and 64.7% of fibers positive for dystrophin. These are biological findings; longer-term functional benefit remains to be established. Use under age 4 remains investigational.
The company reported no new safety signals in older patients; safety in children under 3 was described as manageable and consistent with the known profile. That does not negate ELEVIDYS’ known serious liver-injury and other safety risks, alter the approved label or settle the separate PMO/ESSENCE regulatory questions. September 30 issuer release, Business Wire
The FDA’s November 2025 label action added a boxed warning for serious liver injury and acute liver failure, including fatal outcomes, and removed the non-ambulatory indication. U.S. approval is now for ambulatory Duchenne patients aged four and older. The FDA also required an observational liver-safety study. This is the current regulatory starting point; historical language describing a broader licensed population is obsolete.
Sources: FDA ELEVIDYS label and boxed warning, November 14, 2025.
ENDEAVOR cohort 8 is studying approximately 25 non-ambulatory participants using sirolimus beginning before infusion and continuing afterward. The protocol examines acute liver injury and micro-dystrophin expression at 12 weeks. The latest quarterly timetable points to full-cohort 12-week data in Q1 2027, following expected enrollment completion by year-end 2026.
Sources: ENDEAVOR cohort 8 study design, March 16, 2026 · Q2 2026 results and outlook, August 5, 2026.
A fair reading stays patient-centered and statistically restrained. A small cohort without a severe event could be encouraging, but it would not rule out a rare catastrophic event. Adding immunosuppression also creates its own clinical-management questions. The dataset needs the severity and timing of laboratory abnormalities, infections, serious events, treatment discontinuations and expression results, together with follow-up duration. An encouraging outcome would support a conversation with regulators; it would not by itself restore commercial authorization for non-ambulatory patients.
NMSG update, September 25-27, 2026. ENDURE reported 56 treated participants at its February 2026 cutoff. Treatment-related liver injury occurred in 9/56, including seven serious cases; none occurred in the 11 receiving prophylactic sirolimus. Two deaths included previously reported treatment-related liver failure and unrelated empyema/sepsis. This observational subgroup is small, with site concentration and variable dosing; it cannot show prevention. ENDURE poster.
A separate U.S. postmarketing analysis covered 715 patients through November 2, 2025: 57 serious liver-injury events and 50 related hospitalizations. It includes a fatal liver-failure case already reported, not a newly occurring weekend death. Spontaneous reporting is incomplete and cannot support direct incidence comparisons with ENDURE; the populations cannot be pooled. Postmarketing poster. Neither poster changes the current ambulatory-only indication or boxed warning.
| Program | Disease / target | Status and investment treatment |
|---|---|---|
| SRP-1002 | Idiopathic pulmonary fibrosis / MMP7 | Clinical program; as of October 2, 2026, the company had not announced a major result date through March 2027. |
| SRP-1004 | Spinocerebellar ataxia type 2 / ATXN2 | Clinical program; longer-horizon research optionality. |
| SRP-1005 — INSIGHTT | Huntington’s disease / HTT | Phase 1 dosing underway by August 2026; early safety and exposure development. |
| SRP-1006 / SRP-1007 | SCA3 / SCA1 | Discovery or preclinical programs in the company inventory. |
| SRP-9003 | LGMD2E/R4 / beta-sarcoglycan gene therapy | Clinical hold since July 2025 remained in place in the Q2 2026 filing; the FDA requires sirolimus data before accepting a BLA, and Sarepta plans to re-engage after ENDEAVOR cohort 8 data. |
Sources: Sarepta pipeline, April 2026 program inventory · SRP-1005 INSIGHTT announcement, January 7, 2026 · Q2 2026 results and outlook, August 5, 2026 · June 30, 2026 Form 10-Q, SEC.
A license signed in Q2 2026 contributed $10.0 million of license revenue, according to the June 2026 filing; this is license revenue, not product sales. Sarepta Q2 2026 Form 10-Q.
| Measure | Reported amount | Period / basis |
|---|---|---|
| Net product revenue | $328.7 million | Q2 2026 |
| PMO / ELEVIDYS product mix | $230.6m / $98.1m | Q2 2026 |
| Total revenue | $401.3 million | Q2; includes collaboration and other revenue |
| GAAP operating income / net loss | $13.3m / $(4.9)m | Q2 2026 |
| GAAP R&D / SG&A | $91.3m / $107.6m | Q2 2026 |
| Operating cash flow | $(5.6) million | Six months ended June 30 |
| Headline liquidity | $945.0 million | Cash, investments and restricted cash at June 30 |
| 2026 company guidance | $1.2–1.3 billion | Net product revenue, narrowed on August 5, 2026 from $1.2–1.4 billion; not total GAAP revenue |
| 2026 expense guidance | $800–850 million | Combined non-GAAP R&D and SG&A, narrowed from $800–900 million |
| First-half net product revenue | $659.2 million | Six months ended June 30, 2026 |
Sources: Q2 2026 results and outlook, August 5, 2026 · June 30, 2026 Form 10-Q, SEC.
The first-half income statement requires special care. It included $325 million of recognition from previously deferred Roche revenue, while first-half net income was $326.1 million. Revenue recognition and cash collection are different events. Treating that profit as a repeatable annual earnings base would distort valuation. The first half also included a $40.0 million Roche milestone for the first commercial dosing of ELEVIDYS in Japan, another item that should be separated from recurring product demand; no collaboration revenue was recognized from Roche in the second quarter.
The narrowed guidance also defines the second half. With $659.2 million of net product revenue booked in the first six months, the $1.2–1.3 billion range implies roughly $541–641 million for July to December, or about $270–320 million per quarter, against $328.7 million in the second quarter. That is a Merlintrader calculation, not company guidance for any single quarter; it shows that the range allows for a lower run rate in the second half than in Q2.
Sources: June 30, 2026 Form 10-Q, SEC · Q1 2026 results, May 6, 2026.
| Measure / date | USD million |
|---|---|
| PMO therapies | 230.600 |
| ELEVIDYS | 98.100 |
| Measure / date | USD million |
|---|---|
| Dec 31, 2025 | 953.800 |
| Mar 31, 2026 | 748.300 |
| Jun 30, 2026 | 945.000 |
At June 30, cash plus short- and long-term investments totaled approximately $933.9 million before restricted cash. Convertible-note principal totaled approximately $1.052 billion: $158.6 million due in 2027 and $893.4 million due in 2030. The 2027 notes carry a 1.25% coupon and mature on September 15, 2027; the 2030 notes carry 4.875% and mature on September 1, 2030. Their combined carrying value was $847.6 million, but principal, rather than the discounted accounting carrying value, is the relevant starting point for repayment analysis. Capped calls entered alongside the 2027 notes are designed to reduce dilution on conversion. Ordinary shares outstanding were 105,627,021 at July 31; this is not a fully diluted total.
Two further facts shape the funding picture. Sarepta has a five-year, $600.0 million senior secured revolving credit facility with JPMorgan Chase as agent; during the first half of 2026 it drew and repaid $425.0 million, and nothing was outstanding at June 30. In the 10-Q, management states that cash, investments, operating inflows and the revolver are sufficient to fund the current operating plan for at least twelve months from the filing. On the equity side, 12.2 million shares were subject to outstanding awards at June 30, with about 6.6 million shares available under the 2026 Equity Incentive Plan and about 2.0 million under the 2024 inducement plan, from which 211,070 restricted stock units were granted on September 30, 2026.
Sources: June 30, 2026 Form 10-Q, SEC.
The licensing economics also matter. The Arrowhead arrangement contains annual fees, milestones and royalties; the 2025 annual filing described five $50 million annual installments, subject to the agreement’s terms. A $200 million DM1 milestone was paid in January 2026, and the 10-Q puts potential development, regulatory and sales milestones payable to Arrowhead at up to $10.3 billion over the life of the agreement. The $39.0 million patent settlement of September 23, 2026 is a further cash outflow within ten days of signing. These obligations are part of the cost of creating the next franchise, and belong in any model even though they are less regular than salaries or trial invoices.
Sources: 2025 Form 10-K, filed March 2, 2026 · June 30, 2026 Form 10-Q, SEC · September 23, 2026 Form 8-K · Inducement grants, September 30, 2026.
Several financing mechanisms can affect existing holders: equity compensation increases potential share supply; conversion provisions may create dilution under their contractual conditions; refinancing can exchange a near-term maturity for a higher interest burden; and an equity raise after a favorable data release may trade dilution for reduced execution risk. The balance-sheet test is whether the operating business and available financing can fund the clinical plan while preserving adequate flexibility if a catalyst disappoints.
| Reporting holder | Beneficial ownership | Position date / caveat |
|---|---|---|
| BlackRock | 16,642,620 shares; 15.8% | June 30, 2026; July 30 filing |
| State Street | 8,916,103 shares; 8.4% | June 30, 2026; August 7 filing |
| Vanguard Portfolio Management | 8,499,421 shares; 8.05% | June 30, 2026; July 31 filing |
| AQR | 5,329,691 shares; 5.05% | June 30, 2026; includes convertible-note equivalents for 1,004,002 shares |
Sources: BlackRock Schedule 13G/A, June 30 holdings · State Street Schedule 13G, June 30 holdings · Vanguard Portfolio Management Schedule 13G/A, June 30 holdings · AQR Schedule 13G/A, June 30 holdings.
These are filed beneficial-ownership positions, not live holdings or a vote of confidence in the next trial result. Passive portfolios, index replication, securities lending and hedged strategies can all produce positions whose economic purpose differs from a discretionary long-only clinical thesis. AQR’s explicit convertible component is one reason not to equate a reported share count with an unhedged directional bet.
Some market-data services display institutional ownership above 100%; Finviz showed 106.10% on October 2, 2026, with insider ownership at 4.91%. Merlintrader does not present that aggregate as a literal percentage of unique shares owned: reporting dates, aggregation methods and position definitions differ. The named SEC filings are more useful than an unexplained aggregate. Insider ownership estimates also vary by service and can include different instruments. The recent insider filings described below are equity awards and tax-related transactions, not discretionary open-market purchases.
The most recent insider filings illustrate the point. On September 8, 2026, four executive officers filed Form 4 reports for September 4, 2026: the company withheld shares at $22.22 to cover taxes on restricted stock units granted on September 3, 2025. Chief Financial Officer Ryan Wong had 13,272 shares withheld, Chief Operating Officer Ian Estepan 24,799, General Counsel Cristin Rothfuss 22,025 and Louise Rodino-Klapac, President of R&D and Technical Operations, 21,423. Transaction code F identifies tax withholding, not open-market selling, and the four retained 121,792, 177,184, 115,519 and 203,900 shares respectively.
Sources: Form 4, R. Wong · Form 4, I. Estepan · Form 4, C. Rothfuss · Form 4, L. Rodino-Klapac · Finviz ownership aggregates, October 2, 2026.
Dyne is relevant in two distinct ways. Its z-rostudirsen program targets exon 51 Duchenne, with a January 21, 2027 FDA target date set when the agency accepted the BLA under priority review, as Dyne announced on July 20, 2026. That is a potential competitive development for EXONDYS 51, subject to approval and eventual product characteristics. Its z-basivarsen DM1 program plans a Q1 2027 registrational expansion readout. Those are peer events, not Sarepta catalysts, but they can change the standard investors expect from Sarepta’s data.
Sources: Dyne Q2 2026 results and regulatory milestones · Dyne BLA acceptance, July 20, 2026.
Novartis is another central comparator following its acquisition of Avidity. Del-brax’s FORTITUDE biomarker cohort met its key endpoints in FSHD, and the company is pursuing Phase III development. In DM1, the HARBOR primary-endpoint miss demonstrates the difficulty of translating early biological activity into a statistically persuasive pivotal result. Together these developments create a demanding environment: Sarepta must show why its approach is competitive without relying on simplistic cross-trial percentage comparisons.
Sources: Novartis FORTITUDE results, June 11, 2026 · Novartis HARBOR Phase III results, September 8, 2026.
On September 23, Sarepta entered a settlement with REGENXBIO, UPenn and Catalent concerning specified AAV patent disputes. Sarepta agreed to pay $39 million within ten days. The agreement includes releases and covenants not to sue covering specified patent claims and products using the AAVrh74 capsid, including ELEVIDYS. It does not include an admission of liability or wrongdoing. The expense had already been accrued in Q2.
Sources: September 23, 2026 patent-settlement Form 8-K.
The accounting and investment implications differ. Because the cost was accrued before signature, the September announcement is not a wholly new hit to Q2 earnings. Paying the settlement still consumes cash. Resolution of these particular disputes reduces one category of uncertainty, but it does not show broad freedom to operate for every future program or resolve clinical, reimbursement and regulatory risks. Intellectual-property questions are program-specific, especially as the company combines internally developed products with licensed technologies.
| Timing | Event | Classification | What changes the analysis |
|---|---|---|---|
| September 30, 2026 | WMS Duchenne presentations | Presented September 30; supportive, externally controlled evidence | Older ambulatory ELEVIDYS outcomes, longer follow-up and ESSENCE analyses. Scientific detail can matter, but several posters are not several independent pivotal readouts. |
| Remainder of H2 2026 | SRP-1001 / SRP-1003 repeat-dose data | Major clinical evidence window; exact date not announced | Assess exposure, target response, clinical direction and safety. Grouped conservatively because disclosures could occur together. |
| January 21, 2027 | Dyne z-rostudirsen FDA target date (peer event) | Competitive read-through, not a Sarepta catalyst | An approval would add an exon 51 competitor to EXONDYS 51; the label and data will matter more than the headline. |
| February 28, 2027 | AMONDYS 45 / VYONDYS 53 FDA action | Major regulatory target date | Shared date and ESSENCE evidence base: one event block. Target dates can change. |
| Q1 2027 | ENDEAVOR cohort 8 full-cohort 12-week data | Material safety / development window | Acute liver injury and expression under enhanced immunosuppression. Does not itself restore the non-ambulatory label. |
Sources: WMS presentations announced September 25, 2026 · Q2 2026 results and outlook, August 5, 2026 · FDA accepts AMONDYS 45 and VYONDYS 53 sNDAs, June 30, 2026 · ENDEAVOR cohort 8 study design, March 16, 2026.
The two principal event blocks are separated in time: repeat-dose siRNA data are guided for the remaining portion of 2026, while the PMO decision has a February 2027 target. The full ENDEAVOR dataset adds a third research checkpoint in Q1. The calendar deliberately avoids assigning day-level precision to a quarterly window. It also avoids counting the two PMO applications twice, or treating enrollment completion as equivalent to a clinical efficacy result.
The October 1, 2026 close of $17.57 and 105,627,021 ordinary shares imply equity value near $1.86 billion. That figure sits before any adjustment for the $945.0 million of gross liquidity at June 30, 2026 or the roughly $1.052 billion of convertible-note principal, which broadly offset each other. That establishes the scale of the company; it does not show a bargain. A useful framework separates the risk-adjusted value of existing commercial cash flows, future siRNA economics and other assets, then subtracts debt and remaining funding needs. A product-sales multiple alone cannot capture a regulatory change affecting the durability of those sales.
Sources: Nasdaq historical prices, October 1, 2026 close · June 30, 2026 Form 10-Q, SEC.
The largest valuation mistake would be to capitalize a one-time accounting gain as recurring profit while assigning full commercial value to early programs. A second mistake would be to subtract gross cash without recognizing debt or the spending needed to reach the next milestones. The analysis therefore offers a framework and observable scenarios rather than an unsupported numerical target.
Analyst coverage: dated broker actions reported by Dow Jones Newswires are listed in the latest news above; this page shows no target-price table, and aggregated consensus figures are not a measure of fair value.
The September 15 settlement report showed 25.43 million shares short. Finviz estimates 25.32% of float. Against an estimated float of about 100.44 million shares, as of October 2, 2026, this is a substantial short position in a liquid stock, not an ultra-thin float in which any buying necessarily creates a squeeze. The next settlement report, for September 30, had not been published by October 2, 2026.
Sources: Nasdaq short interest, September 15, 2026 settlement · Finviz float estimate and short % of float, October 2, 2026.
Sentiment on Stocktwits, Reddit and X reflects non-professional traders and is not a substitute for a filing or trial dataset. Borrow availability, options positioning and dealer exposures are not publicly reported at the required granularity, so squeeze claims built on them cannot be tested; the dated short report and company catalysts can still be analysed.
SRPT fits a high-risk catalyst watchlist because its market capitalization is modest relative to the scale of its commercial business and scientific opportunities, current ordinary shares remain below 150 million, and a substantial reported short position can amplify changes in expectations. The same profile carries a serious downside mechanism: regulatory risk in marketed products can reduce the cash engine before early-stage replacements have proved themselves.
Research status: event and source review, not a completed valuation underwrite. Primary documents support the major regulatory dates, trial designs and reported financials. Clinical outcomes, future financing choices and stock reactions remain uncertain. This is educational analysis, not a recommendation to buy, sell or hold, and it is not medical advice.
The source hierarchy is company filings, FDA documents and original clinical materials, followed by market-data providers. Company forecasts are identified as guidance; interpretations and scenarios are editorial analysis. June ownership snapshots, July share counts, the September 15 short-interest settlement and the October 1 reference price deliberately retain their different dates.
Known limitations: no independent patient-level reanalysis; no live borrow or options data; no current social-sentiment score; no complete probability-weighted valuation or fully diluted capitalization model. Reported ordinary shares exclude contingent future dilution. Conference presentations may reuse previously disclosed data. Forward-looking company windows can change.
The FDA’s target action date is February 28, 2027, for the applications that seek traditional approval of AMONDYS 45 and VYONDYS 53. The agency accepted them in June 2026; the supporting ESSENCE trial missed its primary endpoint.
In 25 patients dosed at ages 8–12, the two-year NSAA change was 3.32 points better than in 99 external controls (nominal p=0.0022). The comparison is not randomized and does not change the U.S. label.
Since November 14, 2025, ambulatory Duchenne patients aged four and older, under a boxed warning for acute liver injury and acute liver failure. Non-ambulatory use is being studied with sirolimus in ENDEAVOR cohort 8, with data guided for Q1 2027.
At June 30, 2026: $945.0 million of cash, investments and restricted cash, $158.6 million of notes due 2027 and $893.4 million due 2030, and an undrawn $600.0 million revolver.
No. It is editorial and educational research based on public filings and releases.
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $SRPT or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
